Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
patient experienced febrile seizures after receiving first dose of MMRII; This spontaneous report was received from a Physician and refers to a 16-month-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (dose, frequency, anatomical site, route of administration, lot # and expiration date were not reported) indicated as prophylaxis. The vaccine was reconstituted with sterile diluent (Hollister-Stier STERILE DILUENT), (route, dose, dose number, lot # and expiration date were not reported). On an unknown date, the patient experienced patient experienced febrile seizures (febrile convulsion) after receiving first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II). The patient recovered from the event febrile on an unspecified date. The action taken with sterile diluent and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) was not applicable. The causal relationship between the event of febrile seizures, sterile diluent (Hollister-Stier STERILE DILUENT), and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) was not provided.